Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two Indian Drug Makers Make Acquisition Moves Abroad

This article was originally published in PharmAsia News

Executive Summary

Two more Indian drug makers have moved to buy at least part of foreign firms as the industry continues acquiring other assets. Dr. Reddy's Laboratories said it would buy the U.S. pharmaceutical contract manufacturing business of BASF, but did not disclose what it would be paying. Strides Arcolab said it would buy a larger stake in Genepharm Australasia, enough to give it 55 percent ownership of the Australian firm. In return for its equity stake, Strides said it would sell Genepharm its other Australian and Asian interests for $57.3 million. (Click here for more

You may also be interested in...



GSK Inks “Transformational” Licensing Agreement With Onco Therapies To Extend Reach In Emerging Markets

MUMBAI - British drug maker GlaxoSmithKline has announced a comprehensive product licensing deal, in what it calls a "transformational agreement" with Onco Therapies - a joint venture between South Africa's largest drug firm Aspen Pharmacare and one of India's largest generic drug exporters Strides Arcolab

Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel